PubMed:17978129 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":97,"end":107},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":108,"end":327},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":328,"end":336},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":337,"end":468},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":469,"end":650},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":651,"end":659},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":660,"end":775},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":776,"end":902},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":903,"end":1129},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1130,"end":1347},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1348,"end":1498},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1499,"end":1510},"obj":"Sentence"},{"id":"TextSentencer_T14","span":{"begin":1511,"end":1802},"obj":"Sentence"},{"id":"TextSentencer_T15","span":{"begin":1803,"end":1825},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"T2","span":{"begin":97,"end":107},"obj":"Sentence"},{"id":"T3","span":{"begin":108,"end":327},"obj":"Sentence"},{"id":"T4","span":{"begin":328,"end":336},"obj":"Sentence"},{"id":"T5","span":{"begin":337,"end":468},"obj":"Sentence"},{"id":"T6","span":{"begin":469,"end":650},"obj":"Sentence"},{"id":"T7","span":{"begin":651,"end":659},"obj":"Sentence"},{"id":"T8","span":{"begin":660,"end":775},"obj":"Sentence"},{"id":"T9","span":{"begin":776,"end":902},"obj":"Sentence"},{"id":"T10","span":{"begin":903,"end":1129},"obj":"Sentence"},{"id":"T11","span":{"begin":1130,"end":1347},"obj":"Sentence"},{"id":"T12","span":{"begin":1348,"end":1498},"obj":"Sentence"},{"id":"T13","span":{"begin":1499,"end":1510},"obj":"Sentence"},{"id":"T14","span":{"begin":1511,"end":1802},"obj":"Sentence"},{"id":"T15","span":{"begin":1803,"end":1825},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":261,"end":273},"obj":"HP_0100602"}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"17978129-7#164#188#gene7162","span":{"begin":1294,"end":1318},"obj":"gene7162"},{"id":"17978129-7#17#74#diseaseC0162739","span":{"begin":1147,"end":1204},"obj":"diseaseC0162739"}],"relations":[{"id":"164#188#gene716217#74#diseaseC0162739","pred":"associated_with","subj":"17978129-7#164#188#gene7162","obj":"17978129-7#17#74#diseaseC0162739"}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":261,"end":273},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":421,"end":433},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":621,"end":633},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":883,"end":895},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":947,"end":959},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T6","span":{"begin":1355,"end":1367},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T7","span":{"begin":1667,"end":1679},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T8","span":{"begin":1789,"end":1801},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":77,"end":89},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":261,"end":273},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":421,"end":433},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":621,"end":633},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":883,"end":895},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T6","span":{"begin":947,"end":959},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T7","span":{"begin":1355,"end":1367},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T8","span":{"begin":1667,"end":1679},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T9","span":{"begin":1789,"end":1801},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":0,"end":8},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":68,"end":73},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":321,"end":326},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":391,"end":396},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":582,"end":587},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1475,"end":1480},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1645,"end":1650},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":707,"end":718},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T9","span":{"begin":1076,"end":1087},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T10","span":{"begin":1294,"end":1305},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T11","span":{"begin":1576,"end":1587},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T12","span":{"begin":1167,"end":1172},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"preeclampsia_genes","denotations":[{"id":"PD-PreeclampsiaGenes-B_T1","span":{"begin":665,"end":702},"obj":"HGNC:PSG8"},{"id":"PD-PreeclampsiaGenes-B_T2","span":{"begin":998,"end":1035},"obj":"HGNC:PSG8"},{"id":"PD-PreeclampsiaGenes-B_T3","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG8"},{"id":"PD-PreeclampsiaGenes-B_T4","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG8"},{"id":"PD-PreeclampsiaGenes-B_T5","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG8"},{"id":"PD-PreeclampsiaGenes-B_T6","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG8"},{"id":"PD-PreeclampsiaGenes-B_T7","span":{"begin":665,"end":702},"obj":"HGNC:PSG1"},{"id":"PD-PreeclampsiaGenes-B_T8","span":{"begin":998,"end":1035},"obj":"HGNC:PSG1"},{"id":"PD-PreeclampsiaGenes-B_T9","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG1"},{"id":"PD-PreeclampsiaGenes-B_T10","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG1"},{"id":"PD-PreeclampsiaGenes-B_T11","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG1"},{"id":"PD-PreeclampsiaGenes-B_T12","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG1"},{"id":"PD-PreeclampsiaGenes-B_T13","span":{"begin":665,"end":702},"obj":"HGNC:PSG3"},{"id":"PD-PreeclampsiaGenes-B_T14","span":{"begin":998,"end":1035},"obj":"HGNC:PSG3"},{"id":"PD-PreeclampsiaGenes-B_T15","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG3"},{"id":"PD-PreeclampsiaGenes-B_T16","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG3"},{"id":"PD-PreeclampsiaGenes-B_T17","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG3"},{"id":"PD-PreeclampsiaGenes-B_T18","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG3"},{"id":"PD-PreeclampsiaGenes-B_T19","span":{"begin":665,"end":702},"obj":"HGNC:PSG9"},{"id":"PD-PreeclampsiaGenes-B_T20","span":{"begin":998,"end":1035},"obj":"HGNC:PSG9"},{"id":"PD-PreeclampsiaGenes-B_T21","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG9"},{"id":"PD-PreeclampsiaGenes-B_T22","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG9"},{"id":"PD-PreeclampsiaGenes-B_T23","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG9"},{"id":"PD-PreeclampsiaGenes-B_T24","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG9"},{"id":"PD-PreeclampsiaGenes-B_T25","span":{"begin":665,"end":702},"obj":"HGNC:PSG2"},{"id":"PD-PreeclampsiaGenes-B_T26","span":{"begin":998,"end":1035},"obj":"HGNC:PSG2"},{"id":"PD-PreeclampsiaGenes-B_T27","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG2"},{"id":"PD-PreeclampsiaGenes-B_T28","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG2"},{"id":"PD-PreeclampsiaGenes-B_T29","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG2"},{"id":"PD-PreeclampsiaGenes-B_T30","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG2"},{"id":"PD-PreeclampsiaGenes-B_T31","span":{"begin":665,"end":702},"obj":"HGNC:PSG5"},{"id":"PD-PreeclampsiaGenes-B_T32","span":{"begin":998,"end":1035},"obj":"HGNC:PSG5"},{"id":"PD-PreeclampsiaGenes-B_T33","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG5"},{"id":"PD-PreeclampsiaGenes-B_T34","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG5"},{"id":"PD-PreeclampsiaGenes-B_T35","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG5"},{"id":"PD-PreeclampsiaGenes-B_T36","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG5"},{"id":"PD-PreeclampsiaGenes-B_T37","span":{"begin":665,"end":702},"obj":"HGNC:PSG4"},{"id":"PD-PreeclampsiaGenes-B_T38","span":{"begin":998,"end":1035},"obj":"HGNC:PSG4"},{"id":"PD-PreeclampsiaGenes-B_T39","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG4"},{"id":"PD-PreeclampsiaGenes-B_T40","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG4"},{"id":"PD-PreeclampsiaGenes-B_T41","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG4"},{"id":"PD-PreeclampsiaGenes-B_T42","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG4"},{"id":"PD-PreeclampsiaGenes-B_T43","span":{"begin":665,"end":702},"obj":"HGNC:PSG6"},{"id":"PD-PreeclampsiaGenes-B_T44","span":{"begin":998,"end":1035},"obj":"HGNC:PSG6"},{"id":"PD-PreeclampsiaGenes-B_T45","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG6"},{"id":"PD-PreeclampsiaGenes-B_T46","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG6"},{"id":"PD-PreeclampsiaGenes-B_T47","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG6"},{"id":"PD-PreeclampsiaGenes-B_T48","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG6"},{"id":"PD-PreeclampsiaGenes-B_T49","span":{"begin":665,"end":702},"obj":"HGNC:PSG11"},{"id":"PD-PreeclampsiaGenes-B_T50","span":{"begin":998,"end":1035},"obj":"HGNC:PSG11"},{"id":"PD-PreeclampsiaGenes-B_T51","span":{"begin":1252,"end":1289},"obj":"HGNC:PSG11"},{"id":"PD-PreeclampsiaGenes-B_T52","span":{"begin":1375,"end":1412},"obj":"HGNC:PSG11"},{"id":"PD-PreeclampsiaGenes-B_T53","span":{"begin":1534,"end":1571},"obj":"HGNC:PSG11"},{"id":"PD-PreeclampsiaGenes-B_T54","span":{"begin":1685,"end":1722},"obj":"HGNC:PSG11"},{"id":"PD-PreeclampsiaGenes-B_T55","span":{"begin":690,"end":702},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T56","span":{"begin":719,"end":731},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T57","span":{"begin":1023,"end":1035},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T58","span":{"begin":1088,"end":1100},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T59","span":{"begin":1277,"end":1289},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T60","span":{"begin":1306,"end":1318},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T61","span":{"begin":1400,"end":1412},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T62","span":{"begin":1559,"end":1571},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T63","span":{"begin":1588,"end":1600},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T64","span":{"begin":1710,"end":1722},"obj":"HGNC:GP2"},{"id":"PD-PreeclampsiaGenes-B_T65","span":{"begin":707,"end":731},"obj":"HGNC:TPBG"},{"id":"PD-PreeclampsiaGenes-B_T66","span":{"begin":1076,"end":1100},"obj":"HGNC:TPBG"},{"id":"PD-PreeclampsiaGenes-B_T67","span":{"begin":1294,"end":1318},"obj":"HGNC:TPBG"},{"id":"PD-PreeclampsiaGenes-B_T68","span":{"begin":1576,"end":1600},"obj":"HGNC:TPBG"}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":0,"end":8},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":68,"end":73},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":321,"end":326},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":391,"end":396},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":582,"end":587},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1475,"end":1480},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1645,"end":1650},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":1167,"end":1172},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"PD-UBERON-AE-B_T9","span":{"begin":707,"end":718},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T10","span":{"begin":1076,"end":1087},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T11","span":{"begin":1294,"end":1305},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"},{"id":"PD-UBERON-AE-B_T12","span":{"begin":1576,"end":1587},"obj":"http://purl.obolibrary.org/obo/UBERON_0000088"}],"text":"Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.\nOBJECTIVE: To perform gene expression profiling and real-time quantitative reverse-transcription polymerase chain reaction (PCR) analysis to identify biomarkers of preeclampsia in cellular messenger RNA (mRNA) from maternal blood.\nMETHODS: We performed a microarray analysis with five maternal blood samples from women with preeclampsia and five matched control subjects. Up-regulated gene expression was further analyzed through reverse-transcription PCR analysis with 28 consecutive blood samples from women affected with preeclampsia and 29 controls.\nRESULTS: Both pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were selected based on microarray analysis. Reverse-transcription PCR analysis detected significantly increased mRNA concentrations among women in the preeclampsia group. When stratified according to mild or severe preeclampsia, 19.2-fold and 41.8-fold increases in pregnancy-specific beta1 glycoprotein and 8.3-fold and 10.6-fold increases in trophoblast glycoprotein were observed, respectively. Among women with hemolysis, elevated liver enzymes, and low platelet count syndrome, 51.6-fold and 13.1-fold increases in pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein were observed, respectively. In the preeclampsia group, pregnancy-specific beta1 glycoprotein correlated with severity of proteinuria (P\u003c.001) and systolic blood pressure (P=.01).\nCONCLUSION: The mRNA expression of pregnancy-specific beta1 glycoprotein and trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia, and pregnancy-specific beta1 glycoprotein expression is positively correlated with the clinical severity of preeclampsia.\nLEVEL OF EVIDENCE: II."}